#USA #Robbins Geller #San Diego #GeneDx Holdings #WGS

Investor Alert: Lead the Charge in the GeneDx Class Action Lawsuit

If you are an investor who purchased common stock in GeneDx Holdings Corp. (NASDAQ: WGS) during the period from April 16, 2025, to May 4, 2026, significant news has emerged that might offer you a chance to participate in a class action lawsuit. The renowned law firm Robbins Geller Rudman & Dowd LLP has issued a call to action for those who suffered substantial financial losses during this timeframe to potentially lead the class action lawsuit against the company.

Background on GeneDx and the Allegations

GeneDx, a prominent player in the field of genomics and genetic testing services, recently came under scrutiny following a series of troubling events. The class action lawsuit, titled Basma v. GeneDx Holdings Corp., No. 26-cv-00880 (D. Conn.), accuses GeneDx and certain high-ranking executives of violations of the Securities Exchange Act of 1934, particularly connected to a controversial acquisition.

On April 16, 2025, GeneDx revealed plans to acquire Fabric Genomics, a company with a focus on AI-driven genomic interpretation. However, stakeholders argue that during the class period, company officials allegedly provided misleading statements and failed to disclose critical issues regarding Fabric Genomics’ viability that could adversely affect GeneDx's business model and operational success.

Significant Financial Disclosures

The situation escalated on May 4, 2026, when GeneDx announced its financial results for the first quarter of the year. In what was deemed a shocking revelation, the report showed a decline in adjusted gross margin from 74% to 69%, and a stark reduction in projected earnings, slashing estimates from $540-$555 million down to $475-$490 million. Compounding the negative news was an impairment loss of $31.3 million attributed to the acquisition of Fabric Genomics. Following this announcement, GeneDx's stock price plummeted by over 49%, prompting the current lawsuit.

The Role of a Lead Plaintiff

Understanding the lead plaintiff process under the Private Securities Litigation Reform Act of 1995 is crucial for affected investors. Anyone who purchased GeneDx common stock during the specified class period has the opportunity to seek appointment as the lead plaintiff. This position is typically granted to an individual or entity with the most substantial financial interest in the case, while also representing the overall interests of the group or class.

As a lead plaintiff, you will have significant influence over the direction of the lawsuit and the choice of legal representation. It’s essential to recognize that eligibility to partake in any potential recoveries does not hinge on leading the charge. Each affected investor may still pursue claims independently based on their losses.

How to Act

If you're considering joining as a lead plaintiff in the GeneDx class action lawsuit or simply wish to learn more, you can provide your information through the designated link here. Alternatively, you may contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/851-7783 or emailing them at [email protected].

About Robbins Geller Rudman & Dowd LLP

Robbins Geller is a distinguished law firm globally recognized for its work in securities fraud and shareholder rights cases. The firm boasts a remarkable history, being consistently ranked as a leading entity in class action recoveries, which has seen them secure significant financial recoveries for investors. Their expertise and track record lend considerable weight to your potential case against GeneDx.

Make sure to act swiftly; the deadline for seeking appointment as a lead plaintiff in this vital lawsuit is set for August 3, 2026. Protect your rights and explore this opportunity for justice as a stakeholder in GeneDx Holdings Corp.